globenewswire.com
- Reputation Factor
-
2.6
High
Wikipedia citation breadth, not editorial reliability. One citing article gives 1.0; 100 gives 2.5; and 10,000 gives 3.25. More articles increase the multiplier toward 4.0 with diminishing returns; hostname count does not affect it.
- Sites Owned
- 3
- Total Reference Links
- 162
- Total Citations
- 178
- Unique Wikipedia Articles Citing
- 160
Associated Sites
Top Reference Links
| Score | Article | Site | Category | Cited In (Articles) |
|---|---|---|---|---|
| 7.8 |
Galle Gallants begin new chapter in Lanka Premier Leaguehttps://www.globenewswire.com/news-release/2026/05/04/3286576/0/en/galle-gallants-announce-new-ownership-under-gallant-sports-and-media-llc-within-urban-gro-flash-sports-media-ipg-operated-lpl-season-6-ecosystem-pubudu-dassanayake-appointed-head-c.html |
www.globenewswire.com | News | 3 |
| 5.2 |
Citi(R) Presents A Very Special Performance from Coldplay at the Beacon Theatrehttps://www.globenewswire.com/en/news-release/2014/04/24/1002696/0/en/Citi-R-Presents-a-Very-Special-Performance-From-Coldplay-at-the-Beacon-Theatre.html |
www.globenewswire.com | News | 2 |
| 5.2 |
Chips&Media Completes Development of Next-Gen 'AV2' HW Decoder IP, Accelerating Global Market Leadershiphttps://www.globenewswire.com/news-release/2026/06/10/3309684/0/en/Chips-Media-Completes-Development-of-Next-Gen-AV2-HW-Decoder-IP-Accelerating-Global-Market-Leadership.html |
www.globenewswire.com | News | 2 |
| 5.2 |
U.S. FDA grants accelerated approval to Boehringer's Hernexeos as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLChttps://www.globenewswire.com/news-release/2025/08/08/3130334/0/en/U-S-FDA-grants-accelerated-approval-to-Boehringer-s-HERNEXEOS-as-first-orally-administered-targeted-therapy-for-previously-treated-patients-with-HER2-mutant-advanced-NSCLC.html |
www.globenewswire.com | News | 2 |
| 5.2 |
Crinetics Announces FDA Approval of Palsonify (paltusotine) for the Treatment of Adults with Acromegalyhttps://www.globenewswire.com/news-release/2025/09/25/3156767/0/en/Crinetics-Announces-FDA-Approval-of-PALSONIFY-paltusotine-for-the-Treatment-of-Adults-with-Acromegaly.html |
www.globenewswire.com | News | 2 |
| 5.2 |
Turlov Asks FIDE to Remove Candidate Wadim Rosenstein From the Ballot Over Sponsorship Deal With the German Chess Federationhttps://www.globenewswire.com/news-release/2026/09/04/3356405/0/en/turlov-asks-fide-to-remove-candidate-wadim-rosenstein-from-the-ballot-over-sponsorship-deal-with-the-german-chess-federation.html |
www.globenewswire.com | News | 2 |
| 5.2 |
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01https://www.globenewswire.com/news-release/2026/04/27/3281580/0/en/PharmAla-Executes-Binding-Letter-of-Intent-for-Formation-of-Special-Purpose-Vehicle-to-Develop-Patented-Novel-MDXX-Molecule-APA-01.html |
www.globenewswire.com | News | 2 |
| 2.6 |
Novo Nordisk A/S: Wegovy pill approved in the US as first oral GLP-1 for weight managementhttps://www.globenewswire.com/news-release/2025/12/22/3209605/0/en/Novo-Nordisk-A-S-Wegovy-pill-approved-in-the-US-as-first-oral-GLP-1-for-weight-management.html |
www.globenewswire.com | News | 1 |
| 2.6 |
AXionX INC CEO: AXionX Will Connect the Future Through Powerful Computing Capacityhttps://www.globenewswire.com/news-release/2026/09/02/3355391/0/en/axionx-inc-ceo-axionx-will-connect-the-future-through-powerful-computing-capacity.html |
www.globenewswire.com | News | 1 |
| 2.6 |
Pasatru (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)https://www.globenewswire.com/news-release/2026/08/19/3347919/0/en/pasatru-garetosmab-grts-first-and-only-fda-approved-treatment-demonstrating-reduction-in-new-heterotopic-ossification-ho-lesions-and-clinician-assessed-flare-ups-in-a-placebo-contr.html |
www.globenewswire.com | News | 1 |